In November 2010, Dr. Anthony S. Fauci presented the Forum’s inaugural C. Everett Koop HIV/AIDS Health Leadership Award to VADM C. Everett Koop, the 13th U.S. Surgeon General for “Advancing the Nation’s Progress in Fighting HIV/AIDS through Distinguished Service, Vision and Leadership”. It was meant to acknowledge public health leaders with courage. Accepting the award, Dr. Koop gave a memorable speech The Early Days of AIDS: As I remember them describing his days as Surgeon General during the Reagan administration and how the 1986 Surgeon General’s Report on AIDS Report sent to every one of the 107 million household in America, came to be. We named the award after C. Everett Koop because of his commitment to service and leadership throughout his career, but especially at a time when others were loath to refer to the virus and its disease by name. We asked Dr. Fauci to present the award because of his similar commitment to service and leadership throughout the HIV epidemic. In his presentation, Dr. Fauci commented: “Personally, and to many of us in the medical and public health fields, Dr. Koop is a courageous hero……. Chick Koop…. always seemed to do what was the most correct, honorable, and appropriate thing for the health of the Nation and the world”.
In September 2011, Dr. Koop returned to Washington to present the award to Tony Fauci – an appropriate sequel honoring the mutual respect between the two men from Brooklyn. In his presentation, Dr. Koop commented on Tony’s character, work ethic, and devotion to constantly contribute to the health of mankind – the kind of leader the AIDS epidemic was made for
As we salute Tony Fauci for his Distinguished Service, Vision and Leadership not just in HIV/AIDS but across Infectious Diseases, adding our appreciation for his service to the Nation during the COVID-19 pandemic, it is fitting that we reflect on the award named after the most famous Nation’s Doctor for courage in leadership.
- Veronica Miller
A Tribute
Appreciation and Thanks
2022 Year in Review
2022 Year in Review: Cheers and Happy Holidays from The Forum!
Forum for Collaborative Research
HBV | HIV | Liver | PSC | Rare Diseases | TAVI-CMV | Ocular Diseases | Data & Analysis Center
Dear Forum Stakeholders,
2022 was a year of remarkable growth for the Forum. Truly a special year because we were able to convene many of our projects in-person. As we get ready to welcome 2023, we want to pause and share some highlights of 2022:
New Team Members:
Chris Hoffman, PhD IT and Operational Director
Logan Donaldson, MPH Research Associate
Sehyr Khan, BA Research Associate
Mitchell Leus, MPH Research Associate
Shilpa Mitra, MPH Research Associate
Zach Rooney, MSCS Research Associate
Alicia Jellinek Program Financial Analyst
Nayri Alajaji Graduate Student Researcher
Mayland Treat Graduate Student Researcher
HIV Forum Research Grants and Gifts:
Bill and Melinda Gates Foundation: $1,584,618 to further work on novel trial designs for HIV prevention and conversations related to making new HIV prevention products available to the public.
Gilead Sciences, Inc.: $1,638,338 to help accelerate HIV PrEP research by strengthening counterfactual incidence estimates using a collaborative approach to combine data from multiple sources, informing future trials and bolstering current ones, while simultaneously leading conversations in responsible and ethical use of trial data and its future implications.
Facilitating next-generation pre-exposure prophylaxis (PrEP) clinical trials using HIV recent infection assays: a consensus statement from the Forum HIV Prevention Trial Design Project.Clinical Pharmacology & Therapeutics. Accepted, in print.
Projects Launched:
Data & Analysis Center: to serve the needs of stakeholders in advancing data science for drug development, thus serving patients most of all.
Ocular Diseases Forum: to advance the regulatory sciences for the treatment of inherited retinal diseases and macular degeneration. Co-chaired by Jim Wang and Claire M. Gelfman.
Towards Accelerating Strategies for Hepatitis B Elimination: Increasing Vaccination Among Adults in High-Impact Settings Symposium: as part of the Forum’s Policy Series, a symposium for strengthening implementation of adult hepatitis B vaccination was convened on November 1, 2022 in Atlanta, GA. The symposium convened clinicians, industry, health departments, viral hepatitis programming agencies, harm reduction coalitions, and community-based organizations to facilitate dialogue aimed at producing strategies for implementing universal hepatitis B vaccination among US adults aged 19 to 59, in support of April 2022 guidance by the Advisory Committee on Immunization Practices (ACIP). An output of this meeting will be a special issue in the Journal of Virus Eradication.
Expanding Inclusion for Long-Acting HIV Treatment Trials: this meeting convened on November 10th, 2022 in Washington DC discussed the need for approaches to and regulatory considerations for expanding inclusion of patients who will benefit most from LA treatment options. The Forum brought together stakeholders from the US FDA’s Division of Antivirals, NIH Office of AIDS Research, NIH National Institute of Drug Abuse, NIH National Institute of Mental Health, AIDS Clinical Trial Group (ACTG), Merck, ViiV, Gilead, among other academic institutions and patient advocate groups. Outputs of this meeting include a series of recommendations to be released in 2023.
Next Generation PrEP: Science, policy, and community impact
CODE
SA039
SESSION TYPE
Satellite
ROOM/CHANNEL
Room 517b/Channel 4
DATE TIME
29 July 18:15 - 19:45
ORGANIZER
The Forum for Collaborative Research
Engaging multiple stakeholders across industry, regulatory agencies, patient groups, and academic research to discuss important considerations for trials in next-generation PrEP products. How do clinical trials best assess efficacy for PrEP when standards of care are highly efficacious? How do regulators approach groundbreaking new trial designs in HIV prevention? How do these trial designs affect patients in the trials and those that may benefit from candidate drugs?
The Use of External Controls in FDA Regulatory Decision Making
Washington DC, June 21, 2021 – The Forum for Collaborative Research announced the publication of “The Use of External Controls in FDA Regulatory Decision Making” in Therapeutic Innovation & Regulatory Science. This review describes the circumstances for approval of 45 products based on pivotal studies leveraging external controls, with retrospective natural history studies as the most common source of control data.
Virtual Award Ceremony honoring the memory of Dr. John G. Bartlett and Dr. Jeffrey Murray's 29 years of service at DAVP, FDA
June 29, 2021 1-2 PM EDT
The John G. Bartlett Award "Catalyzing Clinical Research to Improve Global Health" Presented to
Jeffrey Murray
Deputy Director, Division of Antiviral Products, FDA
The Forum for Collaborative Research (The Forum) invites you to join a celebration to honor the memory of Dr. John G. Bartlett, a pioneer in HIV/AIDS study and treatment, and acknowledge Dr. Jeffrey Murray's twenty-nine years of service at the Division of Antiviral Products at the FDA. During this special celebration, the Forum will inaugurate the John G. Bartlett Award for Catalyzing Clinical Research to Improve Global Health to be presented to Dr. Jeffrey Murray by the FDA Acting Commissioner Dr. Janet Woodcock.
Dr. Murray, a visionary and forward-thinking leader, has promoted and contributed to innovations for approvals of new therapeutics to treat and prevent infectious diseases. For many years, he has inspired and championed the Forum for Collaborative Research’s work-- most recently, inspiring efforts towards advancing the regulatory path for new PrEP agents and developing expert consensus on the use of counterfactual HIV incidence estimates to serve as external controls. Dr. Murray has co-authored seminal peer-reviewed publications and FDA guidance documents for HIV drug development, HIV fixed-dose combinations for the President’s Emergency Plan for AIDS Relief (PEPFAR), and the development of drugs for the treatment of Influenza and Hepatitis C.
Dr. John J. Bartlett served as academic co-chair of the HIV Forum's Executive Committee. He was an internationally recognized visionary leader, a pioneer in HIV/AIDS study and treatment, and a receiver of many awards, including the Alexander Fleming Award for Lifetime Achievement, the Maxwell Finland Award for Scientific Achievement, and the Forum’s C. Everett Koop Public Health Leadership Award. Dr. Bartlett was at the forefront of fighting the AIDS epidemic since the early 1980s; he started an AIDS clinic at Johns Hopkins in 1983, directed clinical trials in Baltimore of new treatments that prevent HIV from replicating, and was co-chair and one of the founding members of the national committee that drafted the first and all subsequent treatment guidelines for HIV-infected patients. Dr. Bartlett was the Stanhope Bayne-Jones Professor of Medicine and Director of the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, where he successfully built the infectious diseases division at the Johns Hopkins Hospital, one of the largest divisions at Johns Hopkins and one of the world's premier centers.
While serving as the HIV Forum’s co-chair, he frequently commented that Jeff Murray should receive an award for his commitment to improving treatment of HIV, viral hepatitis and other viral diseases through innovation in development.
It is an honor for the Forum to take Dr. John Bartlett’s words to heart and present this award, in his name, to Dr. Jeffrey Murray.
We hope you are able to join us in celebrating Dr. John Bartlett's legacy and pay tribute to Dr. Jeffrey Murray for their significant contributions to the fight against infectious diseases and their dedication to the Forum's mission.
For questions, please contact Tamar Tchelidze at
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
If you require an accommodation for effective communication (ASL interpreting/CART captioning, alternative media formats, etc.) please contact Astrud Reed at
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
7-10 days in advance of the event.
Brenda E. Rodriguez, MBA, MS, joins the Forum for Collaborative Research as Deputy Director
Washington DC, May 25, 2021 - We are delighted to announce that Brenda E. Rodriguez has joined the Forum for Collaborative Research, a program at UC Berkeley School of Public Health, as Deputy Director. Brenda comes with significant experience in global health, health sciences, higher education, and business administration. She will play a pivotal role in new Forum initiatives such as the Forum’s Collaborative Data Center at Berkeley Public Health and increasing the reach of our educational and training programs across Berkeley Campus, the US and internationally.
The paper combs through the research to look for the best treatment - a "silver bullet" —to treat pediatric nonalcoholic disease. Read more of the article here.
UC Berkeley Online MPH Program Fellowship Opportunity for International Students
The UC Berkeley Online MPH Program is offering a total of 14 Global Public Health fellowships for international MPH students in 2021.
A generous gift from Gilead Sciences will provide 10 fellowships to students from World Bank designated LMICs.
Four fellowships will be awarded to MPH students based in India thanks to a generous gift from the Morris Family Fund.
Fellows will be selected via a competitive evaluation process. Information about the fellowships and how to apply can be found on the Global Public Health Fellowships – 2021 page.
Hep B Foundation, Hep B United and the HBV Forum to honor Corrina Dan, former HHS official
Washington DC, December 1, 2020 – The Hep B Foundation, Hep B United and the HBV Forum are pleased to name Corrina Dan, RN, MPH, as the 2020 recipient of the Hepatitis B Federal Champion Award for her commitment to eliminating hepatitis B. Ms. Dan will receive the award at the Hep B United Virtual Summit on December 4th.
.png)
